查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012514

疼痛管理治疗市场：2026-2032年全球市场预测（依药物类别、给药途径、适应症、通路和最终用户划分）

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疼痛管理治疗市场价值将达到 900.7 亿美元，到 2026 年将成长至 937.8 亿美元，到 2032 年将达到 1267.5 亿美元，复合年增长率为 5.00%。

主要市场统计数据
基准年 2025 900.7亿美元
预计年份：2026年 937.8亿美元
预测年份 2032 1267.5亿美元
复合年增长率 (%) 5.00%

快速变化的临床、监管和商业环境正在重塑疼痛管理的格局，需要以证据为基础、与相关人员一致的策略。

在临床创新、监管改革和相关人员期望变化的推动下，疼痛管理领域正迅速发展并呈现出多元化的趋势。药理学的进步、对鸦片类药物管理的日益重视以及非药物疗法的加速发展，正在拓展临床医生可选择的治疗方案。因此，治疗模式正从单一的治疗方法转向更个人化和多元化的方法，优先考虑疗效、安全性和功能性结果。

多元化的临床实践、数位疗法和强大的供应链正在融合，重塑治疗模式，加速实施进程。

近年来，医疗保健领域发生了一系列变革性变化，重新定义了疼痛管理、治疗和评估的方法。临床上，人们对多方面镇痛的认识不断加深，将药物疗法和非药物疗法相结合，以改善治疗效果并减少阿片类药物的使用。这项转变的驱动因素包括：关于过度依赖鸦片类药物的长期危害的新证据，以及保险公司鼓励患者坚持使用替代疗法和治疗方案的政策。

关税驱动的供应链重组、近岸外包措施以及支付方的成本担忧，已经重塑了整个产业的营运重点和策略投资。

2025年关税及相关贸易措施的实施，为整个疼痛管理产业的相关人员带来了一系列新的营运和策略考量。对于依赖全球化供应链的製造商而言，关税带来的成本增加促使他们重新评估采购决策、原材料替代品和製造地地点。在许多情况下，企业采取的应对措施包括增加库存缓衝、将关键零件的采购转移到成本更低的国家，或投资近岸外包以降低关税波动带来的风险。

多方面的细分框架整合了药物类别、给药途径、适应症、分销管道和最终用户特征，以确定目标机会。

要了解疼痛管理领域中临床机会与商业性需求的交会点，需要采用细緻的细分观点。按药物类别划分，该领域涵盖辅助镇痛药、局部麻醉剂、非类固醇消炎剂(NSAIDs) 和鸦片类药物。神经性疼痛药物又可细分为抗惊厥药和抗忧郁症； 非类固醇又可细分为 COX-2 抑制剂和传统 NSAIDs；阿片类药物则可细分为强效阿片类药物和弱效阿片类药物。每种药物类别的细分市场都展现出独特的疗效、安全性和监管特征，进而影响处方标准和报销考量。

支付方结构、监管多样性和医疗保健服务模式的区域差异，在美洲、欧洲、中东、非洲和亚太地区形成了不同的商业性路径。

区域趋势对疼痛管理疗法的产品策略、监管管道和商业化方式有显着影响。在美洲，阿片类药物管理政策的率先实施、术前术后护理中多模态治疗方案的广泛应用，以及私人保险公司对保险覆盖范围和报销决策持续的重大影响，共同营造了一种环境，在这种环境下，可证实的实际疗效和经济价值更能引起消费者的共鸣。

这是一个既合作又竞争的市场环境，成熟的製药公司、专业的创新者、医疗设备合作伙伴和数位领域的新参与企业齐聚一堂，共同创造综合治疗解决方案。

疼痛管理领域的竞争动态呈现出多元化的特点，既有老牌製药公司，也有专业研发企业、医疗设备製造商和数位医疗领域的新兴参与企业，它们各自为市场带来不同的优势。老牌製药公司凭藉其广泛的商业化网络、与支付方和医疗服务提供者建立的稳固关係以及深厚的临床试验经验，在市场中占据一席之地，但它们也面临着突破传统阿片类药物产品组合的创新压力。

采取切实可行的策略，加强证据产生、供应链韧性、整合产品设计和个人化市场进入，以确保可持续的竞争优势。

引领当前疼痛管理市场发展的产业领导者应采取以实证医学主导、相关人员为中心的策略，使临床开发与商业性需求保持一致。优先创建可操作的真实世界证据和以患者为中心的结果，以证明功能改善和后续资源利用减少，从而满足临床医生和支付方的需求。根据对医疗保健系统至关重要的终点指标客製化研究设计，以加速处方集采纳和临床应用。

采用严谨的混合方法研究途径，结合专家访谈、文献整合和三角测量分析，以检验策略见解和意义。

本报告整合了混合研究框架的洞见，该框架结合了第一手和第二手研究，以确保结果的稳健性和三角检验。第一手资料包括对临床意见领袖、支付方、医院采购经理和商业部门领导者的结构化访谈，以及咨询小组检验关键主题趋势的讨论。这些定性数据辅以对同行评审文献、监管指南、临床试验註册数据、技术白皮书和公共声明的广泛审查，以建立最新的依证。

以证据为基础的差异化、适应性经营模式和协作创新为重点的结论性、综合性分析，确保了长期采用和价值实现。

总而言之，疼痛管理疗法的市场格局正处于转折点，其特点是临床创新、监管力度加大以及对价值的日益重视。多模态治疗的转变、利用数位科技和医疗设备的辅助性治疗的兴起，以及对具有韧性的供应链的需求，都为产品开发商和服务供应商创造了一个更复杂但也充满机会的环境。成功的关键在于能否产生有意义的真实世界数据，为不同的支付者建立引人注目的价值提案，并部署能够反映当地医疗服务实际情况的高度适应性商业模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 疼痛管理治疗市场：依药物类别划分

  • 辅助止痛药
  • 局部麻醉剂
  • 神经性疼痛药物
    • 抗惊厥药物
    • 抗忧郁症
  • 非类固醇消炎剂
    • COX-2抑制剂
    • 传统非类固醇抗发炎药
  • 阿片类药物
    • 强效阿片类药物
    • 弱阿片类药物

第九章 疼痛管理治疗市场：依给药途径划分

  • 口服
  • 肠外
    • 肌肉内部
    • 静脉
    • 皮下
  • 外用
  • 经皮

第十章 疼痛管理治疗市场：依适应症划分

  • 急性疼痛
  • 慢性疼痛
    • 腰痛
    • 神经性慢性疼痛
    • 骨关节炎
    • 类风湿性关节炎
  • 发炎性疼痛
  • 神经性疼痛

第十一章 疼痛管理治疗市场：依通路划分

  • 离线
  • 在线的

第十二章 疼痛管理治疗市场：依最终使用者划分

  • 门诊手术中心
  • 居家照护设施
    • 安宁疗护
    • 病人家
  • 医院
    • 私立医院
    • 公立医院

第十三章 疼痛管理治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 疼痛管理治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 疼痛管理治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国疼痛管理治疗市场

第十七章：中国疼痛管理治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boston Scientific Corporation
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Johnson & Johnson
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-431388EE3C5C

The Pain Management Therapeutics Market was valued at USD 90.07 billion in 2025 and is projected to grow to USD 93.78 billion in 2026, with a CAGR of 5.00%, reaching USD 126.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 90.07 billion
Estimated Year [2026] USD 93.78 billion
Forecast Year [2032] USD 126.75 billion
CAGR (%) 5.00%

A rapidly evolving clinical, regulatory, and commercial environment reshapes pain therapeutics and requires evidence-driven, stakeholder-aligned strategies

The pain management therapeutics landscape is undergoing a rapid, multi-dimensional evolution driven by clinical innovation, regulatory recalibration, and shifting stakeholder expectations. Advances in pharmacology, greater emphasis on opioid stewardship, and the acceleration of nonpharmacologic adjuncts have collectively broadened the therapeutic toolkit available to clinicians. As a result, treatment paradigms are moving away from one-size-fits-all regimens toward more individualized, multimodal approaches that prioritize efficacy, safety, and functional outcomes.

Simultaneously, payer and provider frameworks are increasingly focused on value-based care, outcome measurement, and cost containment. This environment compels product developers and service providers to substantiate not only clinical benefits but also real-world effectiveness and economic value. Regulatory bodies are responding with enhanced oversight of opioid prescribing, tighter controls around certain adjuvant therapies, and clearer guidance on clinical endpoints.

From a commercial perspective, market access strategies must now accommodate a more fragmented set of stakeholders, including integrated delivery networks, ambulatory surgery centers, home care providers, and digital health platforms. In this context, companies that align clinical evidence generation with pragmatic deployment models and stakeholder-specific value propositions will be best positioned to influence care pathways and gain durable adoption.

Multimodal clinical practices, digital therapeutics, and resilient supply chains converge to reshape treatment paradigms and accelerate adoption pathways

Recent years have seen several transformative shifts that are redefining how pain is treated, measured, and managed across care settings. Clinically, there is growing acceptance of multimodal analgesia that combines pharmacologic and nonpharmacologic modalities to improve outcomes while reducing opioid exposure. This shift is reinforced by emerging evidence on the long-term harms of opioid overreliance and by payer policies that incentivize alternatives and pathway adherence.

Technological innovation is also altering the landscape. Digital therapeutics, remote monitoring, wearable sensors, and telehealth-enabled pain management programs are enabling continuous assessment of patient-reported outcomes and facilitating more responsive titration of therapies. In parallel, advances in drug delivery, including long-acting injectables and transdermal systems, are expanding options for sustained analgesia with improved adherence profiles.

Supply chain and manufacturing resilience have become strategic priorities after global disruptions highlighted vulnerabilities in sourcing and production. Companies are therefore reassessing geographic footprints, diversifying supplier bases, and investing in onshore capabilities to mitigate future shocks. This realignment is occurring alongside a shift in clinical trial design that emphasizes pragmatic endpoints, decentralized enrollment, and patient-centric measures, which together accelerate evidence generation and adoption in real-world practice.

Tariff-induced supply chain recalibration, nearshoring initiatives, and payer cost-concerns reshaped operational priorities and strategic investments across the industry

The imposition of tariffs and related trade measures in 2025 introduced a new set of operational and strategic considerations for stakeholders across the pain therapeutics continuum. For manufacturers that rely on globalized supply chains, tariff-related cost increases have prompted granular re-evaluations of sourcing decisions, input substitution, and manufacturing footprints. In many cases, companies responded by increasing inventory buffers, shifting critical components to alternative, lower-cost sourcing countries, or investing in nearshoring initiatives to reduce exposure to tariff volatility.

These operational adjustments have had secondary effects on product development timelines and commercial strategies. Firms prioritized investments that offered resilience or differentiated value, such as advanced delivery systems or device-drug combinations less vulnerable to commodity price swings. Contract negotiations with distributors and payers now routinely include tariff mitigation clauses and pass-through mechanics, which has influenced pricing discussions and reimbursement negotiations.

At the clinical level, the tariff environment reinforced the importance of cost-effective therapeutic options and accelerated payer interest in therapies that deliver demonstrable reductions in utilization of high-cost services. As a result, companies that can evidence total cost of care benefits or that offer integrated service models gained negotiating leverage. Overall, the tariff context has elevated operational agility and supply chain transparency into core competitive capabilities for industry participants.

A multi-dimensional segmentation framework integrates drug classes, delivery modes, indications, distribution channels, and end-user contexts to reveal targeted opportunities

A nuanced segmentation lens is essential for understanding where clinical opportunity and commercial traction intersect in the pain therapeutics space. Based on drug class, the field spans adjuvant analgesics, local anesthetics, neuropathic pain agents, nonsteroidal anti-inflammatory drugs, and opioids, with the neuropathic pain agents further divided into anticonvulsants and antidepressants, the nonsteroidal category bifurcated into Cox-2 inhibitors and traditional NSAIDs, and the opioid class separated into strong and weak opioids. Each drug-class subsegment exhibits distinct efficacy, safety, and regulatory profiles that shape prescriber preference and reimbursement considerations.

Based on route of administration, therapeutic delivery channels include oral, parenteral, topical, and transdermal options, while the parenteral route itself is differentiated across intramuscular, intravenous, and subcutaneous modalities. Delivery format influences adherence, onset of action, and suitability for ambulatory versus inpatient settings, and it informs the design of clinical trials and real-world evidence programs.

Based on indication, the therapeutic landscape covers acute pain, cancer pain, chronic pain, inflammatory pain, and neuropathic pain, with chronic pain further dissected into low back pain, neuropathic chronic pain, osteoarthritis, and rheumatoid arthritis. Indication-specific outcomes, patient-reported measures, and comorbidity profiles dictate both clinical development priorities and commercialization tactics.

Based on distribution channel, products reach patients through offline and online pathways, with digital pharmacies and telehealth-enabled dispensing changing access dynamics. Finally, based on end user, the marketplace serves ambulatory surgical centers, home care settings, and hospitals, with home care settings subdivided into hospice care and patient home, and hospitals separated into private and public institutions. These end-user distinctions determine procurement cycles, formulary decisions, and required supporting services, and they influence the optimal commercial model for launch and scale.

Regional payer structures, regulatory diversity, and care delivery models create distinct commercial pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on product strategy, regulatory pathways, and commercialization approaches within pain management therapeutics. The Americas continue to exhibit advanced adoption of opioid stewardship policies, widespread integration of multimodal perioperative programs, and significant private payer influence on coverage and reimbursement decisions, creating an environment where demonstrable real-world outcomes and economic value resonate strongly with purchasers.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer architectures require adaptable market access strategies and local evidence generation to support formulary inclusion. Reimbursement rules in several jurisdictions emphasize conservative use of high-cost interventions and favor established nonpharmacologic care pathways, prompting companies to design localized value dossiers and to pursue partnerships with regional health systems.

Across Asia-Pacific, rapid uptake of innovative delivery platforms, expanding ambulatory care infrastructure, and growing investment in home-based services are fostering new channels for distribution and patient engagement. The region also presents opportunities to leverage manufacturing scale and cost efficiencies, though companies must navigate varied regulatory timelines and local clinical practice patterns. Together, these regional contours demand differentiated go-to-market blueprints that align clinical evidence, pricing strategies, and stakeholder engagement to regional payer and provider realities.

A collaborative competitive landscape where pharmaceutical incumbents, specialty innovators, device partners, and digital entrants converge to create integrated therapeutic solutions

Competitive dynamics in the pain therapeutics domain are defined by a mix of legacy pharmaceutical players, specialty developers, device manufacturers, and digital health entrants, each bringing different strengths to market. Incumbent pharmaceutical companies leverage broad commercialization networks, established relationships with payers and providers, and deep clinical trial expertise, but they face pressure to innovate beyond traditional opioid-centric portfolios.

Specialized innovators focus on novel mechanisms of action, advanced delivery systems, and combination product strategies that seek to differentiate on efficacy, safety, or convenience. These firms often pursue strategic alliances with device makers or digital health firms to create integrated solutions that support adherence and remote monitoring. Device manufacturers are increasingly partnering with pharmaceutical developers to co-develop drug-device combinations that extend patent life and improve therapeutic precision.

Digital health companies are introducing behavioral therapies, remote monitoring, and AI-enabled pain-tracking tools that complement pharmacologic regimens and provide meaningful patient-reported outcome data. Collaboration, rather than pure competition, is emerging as a sustainable model; alliances between large manufacturers and agile disruptors enable acceleration of time-to-market while de-risking innovation. Overall, companies that combine robust clinical evidence, differentiated delivery, and clear value propositions for payers and providers are most likely to sustain commercial momentum.

Actionable strategies to strengthen evidence generation, supply chain resilience, integrated product design, and tailored market access for sustained competitive advantage

Industry leaders seeking to navigate the current pain therapeutics environment should pursue evidence-led, stakeholder-centric strategies that align clinical development with commercial imperatives. First, prioritize generation of pragmatic real-world evidence and patient-centered outcomes that demonstrate functional improvement and reductions in downstream resource utilization, thereby meeting the dual needs of clinicians and payers. Align study designs with the endpoints that matter to health systems to accelerate formulary acceptance and clinical adoption.

Second, diversify supply chains and consider onshoring or regional manufacturing to reduce exposure to tariff and trade volatility while ensuring consistent product availability. Transparency in supplier relationships and proactive inventory management will strengthen contracting positions with large health systems. Third, invest in hybrid product models that pair pharmacologic therapies with digital tools or device components to improve adherence, enable remote titration, and produce richer longitudinal data for value demonstration.

Fourth, tailor market access approaches to regional payer architectures and care delivery models, building localized value dossiers and forming partnerships with provider networks for pilot deployments. Finally, cultivate cross-sector collaborations and licensing arrangements to share development risk and accelerate commercialization capacity, focusing on segments where differentiated clinical benefits and durable reimbursement pathways are plausible.

A rigorous mixed-methods research approach combining expert interviews, literature synthesis, and triangulated analyses to validate strategic insights and implications

This report synthesizes insights derived from a mixed-methods research framework combining primary and secondary approaches to ensure robust, triangulated findings. Primary inputs include structured interviews with clinical thought leaders, payers, hospital procurement executives, and commercial leaders, as well as advisory panel discussions that validated key thematic trends. These qualitative inputs were complemented by an extensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, technology white papers, and public policy statements to construct an up-to-date evidence base.

Analytical methods included thematic coding of expert interviews to identify recurring strategic priorities, scenario mapping to explore potential operational responses to tariff shifts, and comparative analysis across delivery formats and indications to surface niche opportunities. The segmentation framework was validated through cross-referencing procurement practices and formulary policies across hospital, ambulatory, and home care settings. Limitations of the methodology include the evolving nature of regulatory guidance and the variability of regional reimbursement rules, which were addressed by including time-bound caveats and by recommending continuous surveillance for policy changes.

Throughout, data integrity was prioritized via source triangulation and expert validation to ensure that conclusions reflect a balanced and pragmatic view of the industry landscape.

Conclusive synthesis emphasizing evidence-driven differentiation, adaptive commercial models, and collaborative innovation to secure long-term adoption and value realization

In summary, the pain management therapeutics landscape is at an inflection point characterized by clinical innovation, heightened regulatory scrutiny, and a stronger emphasis on value. The shift toward multimodal care, the rise of digital and device-enabled adjuncts, and the need for resilient supply chains have together created a more complex but opportunity-rich environment for product developers and service providers. Success will depend on the ability to generate meaningful real-world evidence, to craft compelling value propositions for diverse payers, and to deploy adaptive commercial models that reflect regional care delivery realities.

Companies that embrace collaborative development models, prioritize patient-centric outcomes, and invest in operational flexibility will be better positioned to capture opportunity and mitigate risk. The implications extend across the product lifecycle, from clinical development and regulatory strategy to manufacturing and post-market support. Ultimately, the landscape rewards organizations that can translate clinical differentiation into demonstrable improvements in patient function and health system performance, thereby securing sustainable adoption and long-term relevance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pain Management Therapeutics Market, by Drug Class

  • 8.1. Adjuvant Analgesics
  • 8.2. Local Anesthetics
  • 8.3. Neuropathic Pain Agents
    • 8.3.1. Anticonvulsants
    • 8.3.2. Antidepressants
  • 8.4. Nonsteroidal Anti-Inflammatory Drugs
    • 8.4.1. Cox-2 Inhibitors
    • 8.4.2. Traditional NsaiDs
  • 8.5. Opioids
    • 8.5.1. Strong Opioids
    • 8.5.2. Weak Opioids

9. Pain Management Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Topical
  • 9.4. Transdermal

10. Pain Management Therapeutics Market, by Indication

  • 10.1. Acute Pain
  • 10.2. Chronic Pain
    • 10.2.1. Low Back Pain
    • 10.2.2. Neuropathic Chronic Pain
    • 10.2.3. Osteoarthritis
    • 10.2.4. Rheumatoid Arthritis
  • 10.3. Inflammatory Pain
  • 10.4. Neuropathic Pain

11. Pain Management Therapeutics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Pain Management Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care Settings
    • 12.2.1. Hospice Care
    • 12.2.2. Patient Home
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Pain Management Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pain Management Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pain Management Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pain Management Therapeutics Market

17. China Pain Management Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Boston Scientific Corporation
  • 18.10. Eli Lilly and Company
  • 18.11. Endo International plc
  • 18.12. GlaxoSmithKline plc
  • 18.13. Grunenthal GmbH
  • 18.14. Johnson & Johnson
  • 18.15. Mallinckrodt plc
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Purdue Pharma L.P.
  • 18.20. Sanofi S.A.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Teva Pharmaceutical Industries Ltd.
  • 18.23. Vertex Pharmaceuticals Incorporated
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 284. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 297. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO